ImmunoPrecise Antibodies Unveils AI-Designed GLP-1 Therapies, Potentially Transforming Diabetes Treatment

January 22, 2025

DENVER, Colo., Jan 22, 2025 (247marketnews.com)- ImmunoPrecise Antibodies (NASDAQ: IPA) developed a new class of GLP-1 therapies through artificial intelligence, aiming to enhance the efficacy, safety, longevity, and patient satisfaction in treating diabetes. These AI-designed therapeutics are poised to improve upon current GLP-1 treatments, which are widely used for managing type 2 diabetes and obesity. Created using the company’s proprietary LENS ai platform—an AI-driven system analyzing evolutionary patterns in biological data—these novel AI-generated sequences are optimized to maximize therapeutic performance while improving the patient experience. Key improvements include enhanced patentability, increased stability, resistance to degradation, improved administration routes for better compliance, reduced dosing needs, and more efficient manufacturing processes. Notably, IPA is exploring transdermal delivery as a non-invasive alternative to injections. These AI-generated therapies represent IPA’s first fully AI-developed assets, expanding its portfolio of AI-assisted and laboratory-based therapies.

Current GLP-1 treatment options for diabetes and obesity require frequent injections due to their short half-life. In just two weeks, IPA’s LENS ai platform developed and optimized novel genetic sequences for GLP-1-like constructs, offering potential advantages over existing therapies. The company is investigating whether these optimized genetic constructs could support more efficient dosing regimens and improve patient experience. This rapid sequence generation process demonstrates the transformative power of LENS ai in drug discovery, allowing for faster, more precise drug development across various therapeutic areas.

IPA’s LENS ai platform analyzes evolutionary patterns across species to identify key molecular features. Using its HYFT technology, the potential therapeutics were further refined to enhance binding strength, increase resistance to enzymatic breakdown, and optimize their function. Rather than using chemical modifications, IPA applied rational genetic engineering to improve peptide stability and performance in early-stage studies.

In collaboration with Aldevron, LLC (a Danaher company), IPA also optimized its GLP-1 alternatives for compatibility with nucleic acid-based expression systems. The AI-driven approach tailors genetic sequences to leverage specific delivery enhancements, such as improved gene expression and reduced immune response risks, aiming for long-term, stable therapeutic production within the body during preclinical studies.

Given the small size of the therapeutic molecules and their selected gene therapy delivery vehicle, IPA is investigating the potential for transdermal delivery, offering an alternative to injections. This approach could allow for controlled, steady release of the peptide, improving absorption and patient convenience. The AI-driven optimizations ensure compatibility with this delivery method, setting the stage for further research into non-invasive treatments for metabolic diseases.

Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, commented, “LENS ai’s breakthroughs highlight the unmatched power of our proprietary HYFT patterns. These patterns, unique to IPA, are key to unlocking speed and precision in biologics research. LENS ai is not only accelerating development—it’s reshaping therapeutic innovation itself.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (IPA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.